MASH: Survodutide improves Steatohepatitis and Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is associated with increased morbidity and mortality. GLP-1 receptor agonists have a positive effect, but have no direct influence on the liver because hepatocytes lack GLP-1 receptors. Unidual agonism with the combination of GLP-1 and glucagon receptor agonism is said to improve the results. Survodutide has this dual agonistic function and met the endpoints in a double-blind parallel group study.